Lonza agrees to manufacture and supply human milk oligosaccharides for DuPont

March 22, 2019

DuPont Nutrition & Health has reached an agreement with Lonza Specialty Ingredients in which Lonza will manufacture and supply CARE4U 2’-FL, a human milk oligosaccharide. 

DuPont Nutrition & Health (Copenhagen, Denmark) has reached an agreement with Lonza Specialty Ingredients in which Lonza will manufacture and supply CARE4U 2’-FL, a human milk oligosaccharide (HMO). Naturally-occurring in human milk, HMOs have been shown to support digestive, immune, and cognitive health in infants by modifying the gut microbiota. The development of HMOs is a part of DuPont’s larger microbiome investment strategy. 

“By engaging strategically with Lonza, DuPont will be able to accelerate commercialization and offer high-quality HMOs to customers and prospects. The collaboration with Lonza will play a key role in DuPont’s business growth strategy by focusing on providing high-quality consumer health and wellness products,” said John Rea, global business unit leader, cultures, probiotics, food protection, HMO and fibers, for DuPont Nutrition & Health, in a press release.

CARE4U 2’-FL is produced through microbial fermentation to produce a final product that contains over 98% 2’fucosyllactose, the most abundant of the more than 130 oligosaccharides in human milk. A high purity and density powder, the HMO product is easily incorporated into infant formula and dietary supplements.